Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma Meeting Abstract
| Authors: | Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; Moskowitz, A.; Zelenetz, A.; Ahsanuddin, S.; Callan, D.; Freidin, B.; Porzio, R.; Soiffer, J.; Copeland, A.; Dang, T.; Rademaker, J.; Schoder, H.; Ni, A.; Younes, A. |
| Abstract Title: | Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma |
| Meeting Title: | 14th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Jun 14-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2017-06-07 |
| Start Page: | 54 |
| Language: | English |
| ACCESSION: | 123459643 |
| DOI: | 10.1002/hon.2437_38 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 39 -- Accession Number: 123459643 -- Entry Date: In Process -- Revision Date: 20170608 -- Publication Type: Article -- Supplement Title: Jun2017 Supplement -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work